Larimar Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Larimar Therapeutics Inc LRMR.OQ reported a quarterly adjusted loss of 41 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -34 cents. The mean expectation of twelve analysts for the quarter was for a loss of 48 cents per share. Wall Street expected results to range from -52 cents to -39 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Larimar Therapeutics Inc's reported EPS for the quarter was a loss of 41 cents​.

• The company reported a quarterly loss of $26.18 million.

• Larimar Therapeutics Inc shares had risen by 28.7% this quarter and lost 3.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 0.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Larimar Therapeutics Inc is $18.00, about 79.3% above its last closing price of $3.72

This summary was machine generated from LSEG data August 14 at 11:45 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)